-
1
-
-
84864493727
-
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC
-
22611136 10.1093/eurheartj/ehs104 This publication is of major clinical importance since it presents the guidelines for diagnosis and treatment of heart failure
-
•• McMurray JJ, Adamopoulos S, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012;33:1787-847. This publication is of major clinical importance since it presents the guidelines for diagnosis and treatment of heart failure.
-
(2012)
Eur Heart J
, vol.33
, pp. 1787-1847
-
-
McMurray, J.J.1
Adamopoulos, S.2
Anker, S.D.3
-
2
-
-
78651478726
-
Epidemiology and risk profile of heart failure
-
21060326 10.1038/nrcardio.2010.165
-
Bui AL, Horwich TB, Fonarow GC. Epidemiology and risk profile of heart failure. Nat Rev Cardiol. 2011;8:30-41.
-
(2011)
Nat Rev Cardiol
, vol.8
, pp. 30-41
-
-
Bui, A.L.1
Horwich, T.B.2
Fonarow, G.C.3
-
3
-
-
81455131591
-
Systemic inflammation and cell activation reflects morbidity in chronic heart failure
-
21924921 10.1016/j.cyto.2011.08.029
-
Dixon DL, Griggs KM, Bersten AD, De Pasquale CG. Systemic inflammation and cell activation reflects morbidity in chronic heart failure. Cytokine. 2011;56:593-9.
-
(2011)
Cytokine
, vol.56
, pp. 593-599
-
-
Dixon, D.L.1
Griggs, K.M.2
Bersten, A.D.3
De Pasquale, C.G.4
-
4
-
-
0033617442
-
The changes of circulating tumor necrosis factor levels in patients with congestive heart failure influenced by therapy
-
10362376 10.1016/S0167-5273(99)00008-X
-
Liu L, Zhao SP. The changes of circulating tumor necrosis factor levels in patients with congestive heart failure influenced by therapy. Int J Cardiol. 1999;69:77-82.
-
(1999)
Int J Cardiol
, vol.69
, pp. 77-82
-
-
Liu, L.1
Zhao, S.P.2
-
5
-
-
0018691869
-
Platelet-activating factor. Evidence for 1-O-alkyl-2-acetyl-sn-glyceryl- 3-phosphorylcholine as the active component (a new class of lipid chemical mediators)
-
489536
-
Demopoulos CA, Pinckard RN, Hanahan DJ. Platelet-activating factor. Evidence for 1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine as the active component (a new class of lipid chemical mediators). J Biol Chem. 1979;254:9355-8.
-
(1979)
J Biol Chem
, vol.254
, pp. 9355-9358
-
-
Demopoulos, C.A.1
Pinckard, R.N.2
Hanahan, D.J.3
-
6
-
-
0033771162
-
Role of platelet-activating factor in cardiovascular pathophysiology
-
11015622
-
Montrucchio G, Alloatti G, Camussi G. Role of platelet-activating factor in cardiovascular pathophysiology. Physiol Rev. 2000;80:1669-99.
-
(2000)
Physiol Rev
, vol.80
, pp. 1669-1699
-
-
Montrucchio, G.1
Alloatti, G.2
Camussi, G.3
-
7
-
-
0346849863
-
Platelet activating factor - A molecular link between atherosclerosis theories
-
10.1002/ejlt.200300845
-
Demopoulos C, Karantonis H, Antonopoulou S. Platelet activating factor - a molecular link between atherosclerosis theories. Eur J Lipid Sci Technol. 2003;105:705-16.
-
(2003)
Eur J Lipid Sci Technol
, vol.105
, pp. 705-716
-
-
Demopoulos, C.1
Karantonis, H.2
Antonopoulou, S.3
-
8
-
-
77955663716
-
PAF exerts a direct apoptotic effect on the rat H9c2 cardiomyocytes in Ca2+-dependent manner
-
19237210 10.1016/j.ijcard.2009.01.068
-
Zhao D, Chu WF, Wu L, et al. PAF exerts a direct apoptotic effect on the rat H9c2 cardiomyocytes in Ca2+-dependent manner. Int J Cardiol. 2010;143:86-93.
-
(2010)
Int J Cardiol
, vol.143
, pp. 86-93
-
-
Zhao, D.1
Chu, W.F.2
Wu, L.3
-
9
-
-
57649085638
-
Platelet activating factor (PAF) and activity of its biosynthetic and catabolic enzymes in blood and leukocytes of male patients with newly diagnosed heart failure
-
18955040 10.1016/j.clinbiochem.2008.09.113
-
Detopoulou P, Nomikos T, Fragopoulou E, et al. Platelet activating factor (PAF) and activity of its biosynthetic and catabolic enzymes in blood and leukocytes of male patients with newly diagnosed heart failure. Clin Biochem. 2009;42:44-9.
-
(2009)
Clin Biochem
, vol.42
, pp. 44-49
-
-
Detopoulou, P.1
Nomikos, T.2
Fragopoulou, E.3
-
10
-
-
84883054580
-
Baseline and 6-week Follow-Up Levels of PAF and Activity of its Metabolic Enzymes in Patients with Heart Failure and Healthy Volunteers - A Pilot Study
-
doi: 10.1177/0003319712458536
-
• Detopoulou P, Fragopoulou E, Nomikos T, et al. Baseline and 6-week Follow-Up Levels of PAF and Activity of its Metabolic Enzymes in Patients With Heart Failure and Healthy Volunteers - A Pilot Study. Angiology 2012. doi: 10.1177/0003319712458536. This publication presents the whole metabolic circuit of PAF in heart failure patients along with the progression of the disease.
-
(2012)
Angiology
-
-
Detopoulou, P.1
Fragopoulou, E.2
Nomikos, T.3
-
11
-
-
0028982689
-
Platelet-activating factor and its analogs: Metabolic pathways and related intracellular processes
-
7857964 10.1016/0005-2760(94)00192-2
-
Snyder F. Platelet-activating factor and its analogs: metabolic pathways and related intracellular processes. Biochim Biophys Acta. 1995;1254:231-49.
-
(1995)
Biochim Biophys Acta
, vol.1254
, pp. 231-249
-
-
Snyder, F.1
-
12
-
-
34250343830
-
A single enzyme catalyzes both platelet-activating factor production and membrane biogenesis of inflammatory cells: Cloning and characterization of acetyl-CoA:lyso-PAF acetyltransferase
-
17182612 10.1074/jbc.M609641200
-
Shindou H, Hishikawa D, Nakanishi H, et al. A single enzyme catalyzes both platelet-activating factor production and membrane biogenesis of inflammatory cells: cloning and characterization of acetyl-CoA:lyso-PAF acetyltransferase. J Biol Chem. 2007;282:6532-9.
-
(2007)
J Biol Chem
, vol.282
, pp. 6532-6539
-
-
Shindou, H.1
Hishikawa, D.2
Nakanishi, H.3
-
13
-
-
45549107839
-
Identification of a novel noninflammatory biosynthetic pathway of platelet-activating factor
-
18285344 10.1074/jbc.M708909200
-
Harayama T, Shindou H, Ogasawara R, Suwabe A, Shimizu T. Identification of a novel noninflammatory biosynthetic pathway of platelet-activating factor. J Biol Chem. 2008;283:11097-106.
-
(2008)
J Biol Chem
, vol.283
, pp. 11097-11106
-
-
Harayama, T.1
Shindou, H.2
Ogasawara, R.3
Suwabe, A.4
Shimizu, T.5
-
14
-
-
0031552933
-
CDP-choline: Alkylacetylglycerol cholinephosphotransferase catalyzes the final step in the de novo synthesis of platelet-activating factor
-
Snyder F. CDP-choline:alkylacetylglycerol cholinephosphotransferase catalyzes the final step in the de novo synthesis of platelet-activating factor. Biochim Biophys Acta. 1997;4:111-6.
-
(1997)
Biochim Biophys Acta
, vol.4
, pp. 111-116
-
-
Snyder, F.1
-
15
-
-
58549097440
-
Biology of platelet-activating factor acetylhydrolase (PAF-AH, lipoprotein associated phospholipase A2)
-
18949548 10.1007/s10557-008-6133-8
-
Stafforini DM. Biology of platelet-activating factor acetylhydrolase (PAF-AH, lipoprotein associated phospholipase A2). Cardiovasc Drugs Ther. 2009;23:73-83.
-
(2009)
Cardiovasc Drugs Ther
, vol.23
, pp. 73-83
-
-
Stafforini, D.M.1
-
16
-
-
4244169641
-
The anoxic rat-heart myocyte produces and releases platelet activating (PAF) as a component of its ischemia-like pathology
-
Burghardt C, Janero D. The anoxic rat-heart myocyte produces and releases platelet activating (PAF) as a component of its ischemia-like pathology. J Mol Cell Cardiol. 1987;19:pS69.
-
(1987)
J Mol Cell Cardiol.
, vol.19
-
-
Burghardt, C.1
Janero, D.2
-
17
-
-
0021363335
-
Acetyl glyceryl ether phosphorylcholine (AGEPC). A putative mediator of cardiac anaphylaxis in the guinea pig
-
6692502 10.1161/01.RES.54.2.117
-
Levi R, Burke JA, Guo ZG, et al. Acetyl glyceryl ether phosphorylcholine (AGEPC). A putative mediator of cardiac anaphylaxis in the guinea pig. Circ Res. 1984;54:117-24.
-
(1984)
Circ Res
, vol.54
, pp. 117-124
-
-
Levi, R.1
Burke, J.A.2
Guo, Z.G.3
-
18
-
-
18244416154
-
Isolation of platelet-activating factor (PAF) from ischemic baboon myocardium
-
Annable C, McManus L, Carey K, Pinckard R. Isolation of platelet-activating factor (PAF) from ischemic baboon myocardium. Fed Proc. 1985;44:1271.
-
(1985)
Fed Proc
, vol.44
, pp. 1271
-
-
Annable, C.1
McManus, L.2
Carey, K.3
Pinckard, R.4
-
19
-
-
0024595117
-
Release of platelet-activating factor from ischemic-reperfused rabbit heart
-
2539755
-
Montrucchio G, Alloatti G, Tetta C, et al. Release of platelet-activating factor from ischemic-reperfused rabbit heart. Am J Physiol. 1989;256:H1236-46.
-
(1989)
Am J Physiol
, vol.256
-
-
Montrucchio, G.1
Alloatti, G.2
Tetta, C.3
-
20
-
-
0025195661
-
Production and release of platelet-activating factor by the injured heart-muscle cell (cardiomyocyte)
-
2333409
-
Janero DR, Burghardt C. Production and release of platelet-activating factor by the injured heart-muscle cell (cardiomyocyte). Res Commun Chem Pathol Pharmacol. 1990;67:201-18.
-
(1990)
Res Commun Chem Pathol Pharmacol
, vol.67
, pp. 201-218
-
-
Janero, D.R.1
Burghardt, C.2
-
21
-
-
0023475153
-
PAF-acether induced cardiac dysfunction in the isolated perfused guinea pig heart
-
10.1007/BF00164883
-
Stahl GL, Lefer DJ, Lefer AM. PAF-acether induced cardiac dysfunction in the isolated perfused guinea pig heart. Naunyn Schmiedeberg's Arch Pharmacol. 1987;336:459-63.
-
(1987)
Naunyn Schmiedeberg's Arch Pharmacol
, vol.336
, pp. 459-463
-
-
Stahl, G.L.1
Lefer, D.J.2
Lefer, A.M.3
-
22
-
-
0021691371
-
Effects of acetyl glyceryl ether of phosphorylcholine (platelet activating factor) on ventricular preload, afterload, and contractility in dogs
-
6480824 10.1172/JCI111528
-
Kenzora JL, Perez JE, Bergmann SR, Lange LG. Effects of acetyl glyceryl ether of phosphorylcholine (platelet activating factor) on ventricular preload, afterload, and contractility in dogs. J Clin Invest. 1984;74:1193-203.
-
(1984)
J Clin Invest
, vol.74
, pp. 1193-1203
-
-
Kenzora, J.L.1
Perez, J.E.2
Bergmann, S.R.3
Lange, L.G.4
-
23
-
-
0037444902
-
Role of platelet activating factor in cardiac dysfunction, apoptosis and nitric oxide synthase mRNA expression in the ischemic-reperfused rabbit heart
-
12677282
-
Loucks EB, Godin DV, Walley KR, et al. Role of platelet activating factor in cardiac dysfunction, apoptosis and nitric oxide synthase mRNA expression in the ischemic-reperfused rabbit heart. Can J Cardiol. 2003;19:267-74.
-
(2003)
Can J Cardiol
, vol.19
, pp. 267-274
-
-
Loucks, E.B.1
Godin, D.V.2
Walley, K.R.3
-
24
-
-
0029591576
-
Cardiac ultrastructural effects of the platelet-activating factor and its antagonist BN 52021
-
8871085 10.1016/S0940-2993(11)80329-5
-
Kecskemeti V, Balogh I. Cardiac ultrastructural effects of the platelet-activating factor and its antagonist BN 52021. Exp Toxicol Pathol. 1995;47:463-70.
-
(1995)
Exp Toxicol Pathol
, vol.47
, pp. 463-470
-
-
Kecskemeti, V.1
Balogh, I.2
-
25
-
-
0028864605
-
Inhibition of PAF-acether effects on isolated guinea pig hearts by zinc ions (Zn2+)
-
8546883 10.1007/BF02789148
-
Evangelou A, Kalfakakou V, Benveniste J, Arnoux B. Inhibition of PAF-acether effects on isolated guinea pig hearts by zinc ions (Zn2+). Biol Trace Elem Res. 1995;50:43-55.
-
(1995)
Biol Trace Elem Res
, vol.50
, pp. 43-55
-
-
Evangelou, A.1
Kalfakakou, V.2
Benveniste, J.3
Arnoux, B.4
-
26
-
-
0021709615
-
Effect of platelet activating factor on guinea-pig papillary muscle
-
6086382 10.1007/BF01949729
-
Camussi G, Alloatti G, Montrucchio G, Meda M, Emanuelli G. Effect of platelet activating factor on guinea-pig papillary muscle. Experientia. 1984;40:697-9.
-
(1984)
Experientia
, vol.40
, pp. 697-699
-
-
Camussi, G.1
Alloatti, G.2
Montrucchio, G.3
Meda, M.4
Emanuelli, G.5
-
27
-
-
0025098285
-
Effects of platelet-activating factor on single potassium channel currents in guinea pig ventricular myocytes
-
2329995 10.1007/BF00223494
-
Wahler GM, Coyle DE, Sperelakis N. Effects of platelet-activating factor on single potassium channel currents in guinea pig ventricular myocytes. Mol Cell Biochem. 1990;93:69-76.
-
(1990)
Mol Cell Biochem
, vol.93
, pp. 69-76
-
-
Wahler, G.M.1
Coyle, D.E.2
Sperelakis, N.3
-
28
-
-
0026344121
-
Molecular and cellular actions of platelet-activating factor in rat heart cells
-
1661298 10.1172/JCI115540
-
Massey CV, Kohout TA, Gaa ST, Lederer WJ, Rogers TB. Molecular and cellular actions of platelet-activating factor in rat heart cells. J Clin Invest. 1991;88:2106-16.
-
(1991)
J Clin Invest
, vol.88
, pp. 2106-2116
-
-
Massey, C.V.1
Kohout, T.A.2
Gaa, S.T.3
Lederer, W.J.4
Rogers, T.B.5
-
29
-
-
10744230726
-
Phosphoinositide 3-kinase gamma-deficient hearts are protected from the PAF-dependent depression of cardiac contractility
-
14613853 10.1016/j.cardiores.2003.08.008
-
Alloatti G, Levi R, Malan D, et al. Phosphoinositide 3-kinase gamma-deficient hearts are protected from the PAF-dependent depression of cardiac contractility. Cardiovasc Res. 2003;60:242-9.
-
(2003)
Cardiovasc Res
, vol.60
, pp. 242-249
-
-
Alloatti, G.1
Levi, R.2
Malan, D.3
-
30
-
-
0028115491
-
Calcium influx in platelet activating factor-induced atrial natriuretic peptide release in rat cardiomyocytes
-
8166260
-
Church DJ, van der Bent V, Vallotton MB, Capponi AM, Lang U. Calcium influx in platelet activating factor-induced atrial natriuretic peptide release in rat cardiomyocytes. Am J Physiol. 1994;266:E403-9.
-
(1994)
Am J Physiol
, vol.266
-
-
Church, D.J.1
Van Der Bent, V.2
Vallotton, M.B.3
Capponi, A.M.4
Lang, U.5
-
31
-
-
0028055148
-
Platelet-activating-factor-induced changes in cardiovascular function and oxyradical status of myocardium in presence of the PAF antagonist CV-6209
-
8285381 10.1177/000331979404500104
-
Gupta JB, Prasad M, Kalra J, Prasad K. Platelet-activating-factor-induced changes in cardiovascular function and oxyradical status of myocardium in presence of the PAF antagonist CV-6209. Angiology. 1994;45:25-36.
-
(1994)
Angiology
, vol.45
, pp. 25-36
-
-
Gupta, J.B.1
Prasad, M.2
Kalra, J.3
Prasad, K.4
-
32
-
-
0027476306
-
Role of platelet-activating factor in polymorphonuclear neutrophil recruitment in reperfused ischemic rabbit heart
-
8434642
-
Montrucchio G, Alloatti G, Mariano F, et al. Role of platelet-activating factor in polymorphonuclear neutrophil recruitment in reperfused ischemic rabbit heart. Am J Pathol. 1993;142:471-80.
-
(1993)
Am J Pathol
, vol.142
, pp. 471-480
-
-
Montrucchio, G.1
Alloatti, G.2
Mariano, F.3
-
33
-
-
0023190890
-
Electrocardiographic alterations induced by AGEPC in Wistar rats in relation to its hypotensive and hematologic effects
-
2885139 10.1016/0742-8413(87)90177-0
-
Tselepis AD, Evangelou A, Tsoukatos D, Demopoulos CA, Kapoulas VM. Electrocardiographic alterations induced by AGEPC in Wistar rats in relation to its hypotensive and hematologic effects. Comp Biochem Physiol C. 1987;87:41-6.
-
(1987)
Comp Biochem Physiol C
, vol.87
, pp. 41-46
-
-
Tselepis, A.D.1
Evangelou, A.2
Tsoukatos, D.3
Demopoulos, C.A.4
Kapoulas, V.M.5
-
34
-
-
0023946397
-
Negative inotropic effect of platelet-activating factor: Association with a decrease in intracellular sodium activity
-
3361438
-
Robertson DA, Wang DY, Lee CO, Levi R. Negative inotropic effect of platelet-activating factor: association with a decrease in intracellular sodium activity. J Pharmacol Exp Ther. 1988;245:124-8.
-
(1988)
J Pharmacol Exp Ther
, vol.245
, pp. 124-128
-
-
Robertson, D.A.1
Wang, D.Y.2
Lee, C.O.3
Levi, R.4
-
35
-
-
0022975734
-
Cardiovascular alterations in the rabbit infused with platelet activating factor (PAF): Effect of kadsurenone, a PAF-receptor antagonist
-
3025124
-
Montrucchio G, Alloatti G, Mariano F, Tetta C, Emanuelli G, et al. Cardiovascular alterations in the rabbit infused with platelet activating factor (PAF): effect of kadsurenone, a PAF-receptor antagonist. Int J Tissue React. 1986;8:497-504.
-
(1986)
Int J Tissue React
, vol.8
, pp. 497-504
-
-
Montrucchio, G.1
Alloatti, G.2
Mariano, F.3
Tetta, C.4
Emanuelli, G.5
-
37
-
-
0036083492
-
Block of the background K(+) channel TASK-1 contributes to arrhythmogenic effects of platelet-activating factor
-
12003807
-
Barbuti A, Ishii S, Shimizu T, Robinson RB, Feinmark SJ. Block of the background K(+) channel TASK-1 contributes to arrhythmogenic effects of platelet-activating factor. Am J Physiol Heart Circ Physiol. 2002;282:H2024-30.
-
(2002)
Am J Physiol Heart Circ Physiol
, vol.282
-
-
Barbuti, A.1
Ishii, S.2
Shimizu, T.3
Robinson, R.B.4
Feinmark, S.J.5
-
38
-
-
0023005585
-
Electrophysiological effects of acetyl glyceryl ether phosphorylcholine on cardiac tissues: Comparison with lysophosphatidylcholine and long chain acyl carnitine
-
3814909 10.1111/j.1476-5381.1986.tb11179.x
-
Nakaya H, Tohse N. Electrophysiological effects of acetyl glyceryl ether phosphorylcholine on cardiac tissues: comparison with lysophosphatidylcholine and long chain acyl carnitine. Br J Pharmacol. 1986;89:749-57.
-
(1986)
Br J Pharmacol
, vol.89
, pp. 749-757
-
-
Nakaya, H.1
Tohse, N.2
-
39
-
-
0024202638
-
The arrhythmogenic effect of platelet activating factor (PAF) is inhibited by PAF antagonist and by substances influencing eicosanoids
-
3248107
-
Mest HJ, Riedel A, Braquet P, Meyer E. The arrhythmogenic effect of platelet activating factor (PAF) is inhibited by PAF antagonist and by substances influencing eicosanoids. Biomed Biochim Acta. 1988;47:S219-23.
-
(1988)
Biomed Biochim Acta
, vol.47
-
-
Mest, H.J.1
Riedel, A.2
Braquet, P.3
Meyer, E.4
-
40
-
-
0029016452
-
Effects of platelet-activating factor antagonists WEB 2086 and BN 50730 on digoxin-induced arrhythmias
-
7479573 10.1111/j.1600-0773.1995.tb00159.x
-
Cakici I, Mataraci N, Ersoy S, et al. Effects of platelet-activating factor antagonists WEB 2086 and BN 50730 on digoxin-induced arrhythmias. Pharmacol Toxicol. 1995;76:343-7.
-
(1995)
Pharmacol Toxicol
, vol.76
, pp. 343-347
-
-
Cakici, I.1
Mataraci, N.2
Ersoy, S.3
-
41
-
-
0022551741
-
Effects of Ginkgo biloba extract on 2 models of experimental myocardial ischemia
-
2947091
-
Guillon JM, Rochette L, Baranes J. Effects of Ginkgo biloba extract on 2 models of experimental myocardial ischemia. Presse Med. 1986;15:1516-9.
-
(1986)
Presse Med
, vol.15
, pp. 1516-1519
-
-
Guillon, J.M.1
Rochette, L.2
Baranes, J.3
-
42
-
-
0023216340
-
The effect of PAF (platelet-activating factor) on experimental cardiac arrhythmias and its inhibition by substances influencing arachidonic acid metabolites
-
3112804 10.1016/0262-1746(87)90051-5
-
Riedel A, Mest HJ. The effect of PAF (platelet-activating factor) on experimental cardiac arrhythmias and its inhibition by substances influencing arachidonic acid metabolites. Prostaglandins Leukot Med. 1987;28:103-9.
-
(1987)
Prostaglandins Leukot Med
, vol.28
, pp. 103-109
-
-
Riedel, A.1
Mest, H.J.2
-
43
-
-
0019510265
-
Antihypertensive lipids from the kidney: Alkyl ether analogs of phosphatidylcholine
-
7016598
-
Muirhead EE, Byers LW, Desiderio DM, Brooks B, Brosius WM. Antihypertensive lipids from the kidney: alkyl ether analogs of phosphatidylcholine. Fed Proc. 1981;40:2285-90.
-
(1981)
Fed Proc
, vol.40
, pp. 2285-2290
-
-
Muirhead, E.E.1
Byers, L.W.2
Desiderio, D.M.3
Brooks, B.4
Brosius, W.M.5
-
44
-
-
79958788029
-
Platelet activating factor: The good and the bad in the ischemic/reperfused heart
-
10.1258/ebm.2011.010316 The present review provides a thorough presentation of the role of PAF in ischemia/ reperfusion with a plethora of experimental examples
-
•• Penna C, Bassino E, Alloatti G. Platelet activating factor: the good and the bad in the ischemic/reperfused heart. Exp Biol Med (Maywood). 2011;236:390-401. The present review provides a thorough presentation of the role of PAF in ischemia/ reperfusion with a plethora of experimental examples.
-
(2011)
Exp Biol Med (Maywood)
, vol.236
, pp. 390-401
-
-
Penna, C.1
Bassino, E.2
Alloatti, G.3
-
45
-
-
0020523662
-
Inactivation of 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine by a plasma acetylhydrolase: Higher activities in hypertensive rats
-
6870880 10.1016/0006-291X(83)91778-3
-
Blank ML, Hall MN, Cress EA, Snyder F. Inactivation of 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine by a plasma acetylhydrolase: higher activities in hypertensive rats. Biochem Biophys Res Commun. 1983;113:666-71.
-
(1983)
Biochem Biophys Res Commun
, vol.113
, pp. 666-671
-
-
Blank, M.L.1
Hall, M.N.2
Cress, E.A.3
Snyder, F.4
-
46
-
-
0023851779
-
Increased levels of platelet-activating factor (1-O-alkyl-2- acetylglycerophosphocholine) in blood after reversal of renal clip hypertension in the rat
-
McGowan HM, Vandongen R, Kelly LD, Hill KJ. Increased levels of platelet-activating factor (1-O-alkyl-2-acetylglycerophosphocholine) in blood after reversal of renal clip hypertension in the rat. Clin Sci (Lond). 1988;74:393-6.
-
(1988)
Clin Sci (Lond)
, vol.74
, pp. 393-396
-
-
McGowan, H.M.1
Vandongen, R.2
Kelly, L.D.3
Hill, K.J.4
-
47
-
-
0026746368
-
Effects of coronary angioplasty on plasma platelet-activating factor in man
-
1467464
-
Eldar M, Lysko PG, Schulhoff N, et al. Effects of coronary angioplasty on plasma platelet-activating factor in man. J Lipid Mediat. 1992;5:313-9.
-
(1992)
J Lipid Mediat
, vol.5
, pp. 313-319
-
-
Eldar, M.1
Lysko, P.G.2
Schulhoff, N.3
-
48
-
-
0022446195
-
Coronary vasoconstriction in the rat, isolated perfused heart induced by platelet-activating factor is mediated by leukotriene C4
-
3091131 10.1111/j.1476-5381.1986.tb10240.x
-
Piper PJ, Stewart AG. Coronary vasoconstriction in the rat, isolated perfused heart induced by platelet-activating factor is mediated by leukotriene C4. Br J Pharmacol. 1986;88:595-605.
-
(1986)
Br J Pharmacol
, vol.88
, pp. 595-605
-
-
Piper, P.J.1
Stewart, A.G.2
-
49
-
-
0023188640
-
Antagonism of vasoconstriction induced by platelet-activating factor in guinea-pig perfused hearts by selective platelet-activating factor receptor antagonists
-
3034369 10.1111/j.1476-5381.1987.tb11231.x
-
Piper PJ, Stewart AG. Antagonism of vasoconstriction induced by platelet-activating factor in guinea-pig perfused hearts by selective platelet-activating factor receptor antagonists. Br J Pharmacol. 1987;90:771-83.
-
(1987)
Br J Pharmacol
, vol.90
, pp. 771-783
-
-
Piper, P.J.1
Stewart, A.G.2
-
50
-
-
84863085792
-
Infection and inflammation as risk factors for thrombosis and atherosclerosis
-
22399308 10.1055/s-0032-1305782
-
Levi M, van der Poll T, Schultz M. Infection and inflammation as risk factors for thrombosis and atherosclerosis. Semin Thromb Hemost. 2012;38:506-14.
-
(2012)
Semin Thromb Hemost
, vol.38
, pp. 506-514
-
-
Levi, M.1
Van Der Poll, T.2
Schultz, M.3
-
51
-
-
0344081893
-
Platelet-activating factor, a pleiotrophic mediator of physiological and pathological processes
-
14708958 10.1080/714037693
-
Stafforini DM, McIntyre TM, Zimmerman GA, Prescott SM. Platelet-activating factor, a pleiotrophic mediator of physiological and pathological processes. Crit Rev Clin Lab Sci. 2003;40:643-72.
-
(2003)
Crit Rev Clin Lab Sci
, vol.40
, pp. 643-672
-
-
Stafforini, D.M.1
McIntyre, T.M.2
Zimmerman, G.A.3
Prescott, S.M.4
-
52
-
-
0025263965
-
Platelet-activating factor may act as a second messenger in the release of eicosanoids and superoxide anions from leukocytes and endothelial cells
-
2158106 10.1073/pnas.87.8.3215
-
Stewart AG, Dubbin PN, Harris T, Dusting GJ. Platelet-activating factor may act as a second messenger in the release of eicosanoids and superoxide anions from leukocytes and endothelial cells. Proc Natl Acad Sci U S A. 1990;87:3215-9.
-
(1990)
Proc Natl Acad Sci U S A
, vol.87
, pp. 3215-3219
-
-
Stewart, A.G.1
Dubbin, P.N.2
Harris, T.3
Dusting, G.J.4
-
53
-
-
0023756138
-
Platelet activating factor is a potent stimulant of the production of active oxygen species by human monocyte-derived macrophages
-
2847729 10.1016/S0006-291X(88)80773-3
-
Rouis M, Nigon F, Chapman MJ. Platelet activating factor is a potent stimulant of the production of active oxygen species by human monocyte-derived macrophages. Biochem Biophys Res Commun. 1988;156:1293-301.
-
(1988)
Biochem Biophys Res Commun
, vol.156
, pp. 1293-1301
-
-
Rouis, M.1
Nigon, F.2
Chapman, M.J.3
-
54
-
-
0035181940
-
Mechanisms for oxidizing low-density lipoprotein. Insights from patterns of oxidation products in the artery wall and from mouse models of atherosclerosis
-
11685998 10.1016/S1050-1738(01)00101-3
-
Gaut JP, Heinecke JW. Mechanisms for oxidizing low-density lipoprotein. Insights from patterns of oxidation products in the artery wall and from mouse models of atherosclerosis. Trends Cardiovasc Med. 2001;11:103-12.
-
(2001)
Trends Cardiovasc Med
, vol.11
, pp. 103-112
-
-
Gaut, J.P.1
Heinecke, J.W.2
-
55
-
-
0028352168
-
Platelet-activating factor formation during oxidative modification of low-density lipoprotein when PAF-acetylhydrolase has been inactivated
-
8199206 10.1016/0005-2760(94)90210-0
-
Liapikos TA, Antonopoulou S, Karabina SP, et al. Platelet-activating factor formation during oxidative modification of low-density lipoprotein when PAF-acetylhydrolase has been inactivated. Biochim Biophys Acta. 1994;1212:353-60.
-
(1994)
Biochim Biophys Acta
, vol.1212
, pp. 353-360
-
-
Liapikos, T.A.1
Antonopoulou, S.2
Karabina, S.P.3
-
56
-
-
79953773696
-
Pivotal role for platelet-activating factor receptor in CD36 expression and oxLDL uptake by human monocytes/macrophages
-
21471725 10.1159/000327962
-
Rios FJ, Gidlund M, Jancar S. Pivotal role for platelet-activating factor receptor in CD36 expression and oxLDL uptake by human monocytes/macrophages. Cell Physiol Biochem. 2011;27:363-72.
-
(2011)
Cell Physiol Biochem
, vol.27
, pp. 363-372
-
-
Rios, F.J.1
Gidlund, M.2
Jancar, S.3
-
57
-
-
2442443131
-
Activation of PAF receptor by oxidised LDL in human monocytes stimulates chemokine releases but not urokinase-type plasminogen activator expression
-
15149885 10.1016/j.cccn.2004.02.030
-
Beaudeux JL, Said T, Ninio E, et al. Activation of PAF receptor by oxidised LDL in human monocytes stimulates chemokine releases but not urokinase-type plasminogen activator expression. Clin Chim Acta. 2004;344:163-71.
-
(2004)
Clin Chim Acta
, vol.344
, pp. 163-171
-
-
Beaudeux, J.L.1
Said, T.2
Ninio, E.3
-
58
-
-
0029988135
-
Inflammation as an early component of atherosclerosis and vascular damage-A role for P-selectin and platelet-activating factor
-
8741238 10.1253/jcj.60.137
-
Prescott SM, McIntyre TM, Zimmerman GA, Stafforini DM. Inflammation as an early component of atherosclerosis and vascular damage-a role for P-selectin and platelet-activating factor. Jpn Circ J. 1996;60:137-41.
-
(1996)
Jpn Circ J
, vol.60
, pp. 137-141
-
-
Prescott, S.M.1
McIntyre, T.M.2
Zimmerman, G.A.3
Stafforini, D.M.4
-
59
-
-
0021656990
-
Effect of platelet activating factor on endothelial permeability to plasma macromolecules
-
6083990 10.1016/0162-3109(84)90017-1
-
Handley DA, Arbeeny CM, Lee ML, Van Valen RG, Saunders RN. Effect of platelet activating factor on endothelial permeability to plasma macromolecules. Immunopharmacology. 1984;8:137-42.
-
(1984)
Immunopharmacology
, vol.8
, pp. 137-142
-
-
Handley, D.A.1
Arbeeny, C.M.2
Lee, M.L.3
Van Valen, R.G.4
Saunders, R.N.5
-
60
-
-
0028913968
-
Monocyte tethering by P-selectin regulates monocyte chemotactic protein-1 and tumor necrosis factor-alpha secretion. Signal integration and NF-kappa B translocation
-
7537762 10.1172/JCI117921
-
Weyrich AS, McIntyre TM, McEver RP, Prescott SM, Zimmerman GA. Monocyte tethering by P-selectin regulates monocyte chemotactic protein-1 and tumor necrosis factor-alpha secretion. Signal integration and NF-kappa B translocation. J Clin Invest. 1995;95:2297-303.
-
(1995)
J Clin Invest
, vol.95
, pp. 2297-2303
-
-
Weyrich, A.S.1
McIntyre, T.M.2
McEver, R.P.3
Prescott, S.M.4
Zimmerman, G.A.5
-
61
-
-
33846089947
-
Neutrophil-activating activity and platelet-activating factor synthesis in cytokine-stimulated endothelial cells: Reduced activity in growth-arrested cells
-
17027041 10.1016/j.mvr.2006.08.002
-
Takahashi T, Nishizawa Y, Hato F, et al. Neutrophil-activating activity and platelet-activating factor synthesis in cytokine-stimulated endothelial cells: reduced activity in growth-arrested cells. Microvasc Res. 2006;73:29-34.
-
(2006)
Microvasc Res
, vol.73
, pp. 29-34
-
-
Takahashi, T.1
Nishizawa, Y.2
Hato, F.3
-
62
-
-
0019450873
-
Human platelet stimulation by acetyl glyceryl ether phosphorylcholine
-
7204562 10.1172/JCI110108
-
McManus LM, Hanahan DJ, Pinckard RN. Human platelet stimulation by acetyl glyceryl ether phosphorylcholine. J Clin Invest. 1981;67:903-6.
-
(1981)
J Clin Invest
, vol.67
, pp. 903-906
-
-
McManus, L.M.1
Hanahan, D.J.2
Pinckard, R.N.3
-
63
-
-
0030760170
-
Platelets and inflammation
-
10.1007/s004290050075
-
Klinger MH. Platelets and inflammation. Anat Embryol (Berl). 1997;196:1-11.
-
(1997)
Anat Embryol (Berl)
, vol.196
, pp. 1-11
-
-
Klinger, M.H.1
-
64
-
-
0025326170
-
Expression of elastase activity by human monocyte-macrophages is modulated by cellular cholesterol content, inflammatory mediators, and phorbol myristate acetate
-
2317158 10.1161/01.ATV.10.2.246
-
Rouis M, Nigon F, Lafuma C, Hornebeck W, Chapman MJ. Expression of elastase activity by human monocyte-macrophages is modulated by cellular cholesterol content, inflammatory mediators, and phorbol myristate acetate. Arteriosclerosis. 1990;10:246-55.
-
(1990)
Arteriosclerosis
, vol.10
, pp. 246-255
-
-
Rouis, M.1
Nigon, F.2
Lafuma, C.3
Hornebeck, W.4
Chapman, M.J.5
-
65
-
-
84855785879
-
PAF, a potent lipid mediator In: Bioactive Phospholipids
-
Edited by Tselepis AD. India: Research Signpost
-
Antonopoulou S, Nomikos T, Karantonis HC, Fragopoulou E, Demopoulos CA. PAF, a potent lipid mediator In: Bioactive Phospholipids. Role in Inflammation and Atheroslerosis. Edited by Tselepis AD. India: Research Signpost; 2009:85-134.
-
(2009)
Role in Inflammation and Atheroslerosis
, pp. 85-134
-
-
Antonopoulou, S.1
Nomikos, T.2
Karantonis, H.C.3
Fragopoulou, E.4
Demopoulos, C.A.5
-
66
-
-
0024311522
-
Protective effect of BN 52021, a specific antagonist of platelet-activating factor (PAF-acether) against diet-induced cholesteryl ester deposition in rabbit aorta
-
2783199 10.1016/0021-9150(89)90219-0
-
Feliste R, Perret B, Braquet P, Chap H. Protective effect of BN 52021, a specific antagonist of platelet-activating factor (PAF-acether) against diet-induced cholesteryl ester deposition in rabbit aorta. Atherosclerosis. 1989;78:151-8.
-
(1989)
Atherosclerosis
, vol.78
, pp. 151-158
-
-
Feliste, R.1
Perret, B.2
Braquet, P.3
Chap, H.4
-
67
-
-
33750452307
-
Molecular mechanisms in heart failure: Focus on cardiac hypertrophy, inflammation, angiogenesis, and apoptosis
-
10.1016/j.jacc.2006.07.007
-
Hilfiker-Kleiner D, Landmesser U, Drexler H. Molecular mechanisms in heart failure: focus on cardiac hypertrophy, inflammation, angiogenesis, and apoptosis. J Am Coll Cardiol. 2006;48:56-66.
-
(2006)
J Am Coll Cardiol
, vol.48
, pp. 56-66
-
-
Hilfiker-Kleiner, D.1
Landmesser, U.2
Drexler, H.3
-
68
-
-
70649095109
-
Signaling pathways of cardioprotective ischemic preconditioning
-
19540944 10.1016/j.ijsu.2009.06.004
-
Sadat U. Signaling pathways of cardioprotective ischemic preconditioning. Int J Surg. 2009;7:490-8.
-
(2009)
Int J Surg
, vol.7
, pp. 490-498
-
-
Sadat, U.1
-
69
-
-
49249089895
-
A cardioprotective role for platelet-activating factor through NOS-dependent S-nitrosylation
-
18441203 10.1152/ajpheart.00269.2008
-
Leary PJ, Rajasekaran S, Morrison RR, et al. A cardioprotective role for platelet-activating factor through NOS-dependent S-nitrosylation. Am J Physiol Heart Circ Physiol. 2008;294:H2775-84.
-
(2008)
Am J Physiol Heart Circ Physiol
, vol.294
-
-
Leary, P.J.1
Rajasekaran, S.2
Morrison, R.R.3
-
70
-
-
0024159710
-
Biphasic platelet-activating factor synthesis by human monocytes stimulated with IL-1-beta, tumor necrosis factor, or IFN-gamma
-
3141509
-
Valone FH, Epstein LB. Biphasic platelet-activating factor synthesis by human monocytes stimulated with IL-1-beta, tumor necrosis factor, or IFN-gamma. J Immunol. 1988;141:3945-50.
-
(1988)
J Immunol
, vol.141
, pp. 3945-3950
-
-
Valone, F.H.1
Epstein, L.B.2
-
71
-
-
78651265503
-
Investigation of platelet activating factor (PAF) in acute myocardial infarction
-
Zhang GQ, Tao YK, Li XL, et al. Investigation of platelet activating factor (PAF) in acute myocardial infarction. Chin J Emerg Med. 2010;19:1304-7.
-
(2010)
Chin J Emerg Med
, vol.19
, pp. 1304-1307
-
-
Zhang, G.Q.1
Tao, Y.K.2
Li, X.L.3
-
72
-
-
77956319420
-
Gene expression profiling in peripheral blood nuclear cells in patients with refractory ischaemic end-stage heart failure
-
20720311 10.1007/BF03208866
-
Szmit S, Jank M, Maciejewski H, et al. Gene expression profiling in peripheral blood nuclear cells in patients with refractory ischaemic end-stage heart failure. J Appl Genet. 2010;51:353-68.
-
(2010)
J Appl Genet
, vol.51
, pp. 353-368
-
-
Szmit, S.1
Jank, M.2
Maciejewski, H.3
-
73
-
-
0035933117
-
Adenovirus-mediated gene transfer of human platelet-activating factor-acetylhydrolase prevents injury-induced neointima formation and reduces spontaneous atherosclerosis in apolipoprotein E-deficient mice
-
11369691 10.1161/01.CIR.103.20.2495
-
Quarck R, De Geest B, Stengel D, et al. Adenovirus-mediated gene transfer of human platelet-activating factor-acetylhydrolase prevents injury-induced neointima formation and reduces spontaneous atherosclerosis in apolipoprotein E-deficient mice. Circulation. 2001;103:2495-500.
-
(2001)
Circulation
, vol.103
, pp. 2495-2500
-
-
Quarck, R.1
De Geest, B.2
Stengel, D.3
-
74
-
-
77951605907
-
Lipoprotein-associated phospholipase A2 and risk of coronary disease, stroke, and mortality: Collaborative analysis of 32 prospective studies
-
The Lp-PLA2 Studies Collaboration 10.1016/S0140-6736(10)60319-4 The present paper presents the combined results of several large studies concerning the role of Lp-PLA2 in cardiovascular disease
-
•• The Lp-PLA2 Studies Collaboration. Lipoprotein-associated phospholipase A2 and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet. 2010;375:1536-44. The present paper presents the combined results of several large studies concerning the role of Lp-PLA2 in cardiovascular disease.
-
(2010)
Lancet
, vol.375
, pp. 1536-1544
-
-
-
75
-
-
34249713287
-
Elevated Lp-PLA2 levels add prognostic information to the metabolic syndrome on incidence of cardiovascular events among middle-aged nondiabetic subjects
-
17431184 10.1161/ATVBAHA.107.142679
-
Persson M, Hedblad B, Nelson JJ, Berglund G. Elevated Lp-PLA2 levels add prognostic information to the metabolic syndrome on incidence of cardiovascular events among middle-aged nondiabetic subjects. Arterioscler Thromb Vasc Biol. 2007;27:1411-6.
-
(2007)
Arterioscler Thromb Vasc Biol
, vol.27
, pp. 1411-1416
-
-
Persson, M.1
Hedblad, B.2
Nelson, J.J.3
Berglund, G.4
-
76
-
-
43049122963
-
The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: The results of a multicenter, randomized, double-blind, placebo-controlled study
-
18436114 10.1016/j.jacc.2007.11.079
-
Mohler 3rd ER, Ballantyne CM, Davidson MH, et al. The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study. J Am Coll Cardiol. 2008;51:1632-41.
-
(2008)
J Am Coll Cardiol
, vol.51
, pp. 1632-1641
-
-
Mohler III, E.R.1
Ballantyne, C.M.2
Davidson, M.H.3
-
77
-
-
54049152760
-
Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque
-
18765397 10.1161/CIRCULATIONAHA.108.771899
-
Serruys PW, Garcia-Garcia HM, Buszman P, et al. Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque. Circulation. 2008;118:1172-82.
-
(2008)
Circulation
, vol.118
, pp. 1172-1182
-
-
Serruys, P.W.1
Garcia-Garcia, H.M.2
Buszman, P.3
-
78
-
-
80052305914
-
Inhibition of lipoprotein-associated phospholipase A2 ameliorates inflammation and decreases atherosclerotic plaque formation in ApoE-deficient mice
-
21909350 10.1371/journal.pone.0023425
-
Wang WY, Zhang J, Wu WY, et al. Inhibition of lipoprotein-associated phospholipase A2 ameliorates inflammation and decreases atherosclerotic plaque formation in ApoE-deficient mice. PLoS One. 2011;6:e23425.
-
(2011)
PLoS One
, vol.6
, pp. 23425
-
-
Wang, W.Y.1
Zhang, J.2
Wu, W.Y.3
-
79
-
-
80053921636
-
The inhibition of lipoprotein-associated phospholipase A2 exerts beneficial effects against atherosclerosis in LDLR-deficient mice
-
21970837
-
Hu MM, Zhang J, Wang WY, et al. The inhibition of lipoprotein-associated phospholipase A2 exerts beneficial effects against atherosclerosis in LDLR-deficient mice. Acta Pharmacol Sin. 2011;32:1253-8.
-
(2011)
Acta Pharmacol Sin
, vol.32
, pp. 1253-1258
-
-
Hu, M.M.1
Zhang, J.2
Wang, W.Y.3
-
80
-
-
77955585234
-
Study design and rationale for the clinical outcomes of the STABILITY Trial (STabilization of Atherosclerotic plaque by Initiation of darapLadIb TherapY) comparing darapladib versus placebo in patients with coronary heart disease
-
20934559 10.1016/j.ahj.2010.07.006
-
White H, Held C, Stewart R, et al. Study design and rationale for the clinical outcomes of the STABILITY Trial (STabilization of Atherosclerotic plaque By Initiation of darapLadIb TherapY) comparing darapladib versus placebo in patients with coronary heart disease. Am Heart J. 2010;160:655-61.
-
(2010)
Am Heart J
, vol.160
, pp. 655-661
-
-
White, H.1
Held, C.2
Stewart, R.3
-
81
-
-
33749029903
-
Lipoprotein-associated phospholipase A2 activity and risk of heart failure: The Rotterdam study
-
16952920 10.1093/eurheartj/ehl230
-
van Vark LC, Kardys I, Bleumink GS, et al. Lipoprotein-associated phospholipase A2 activity and risk of heart failure: the Rotterdam study. Eur Heart J. 2006;27:2346-52.
-
(2006)
Eur Heart J
, vol.27
, pp. 2346-2352
-
-
Van Vark, L.C.1
Kardys, I.2
Bleumink, G.S.3
-
82
-
-
70350462270
-
Lipoprotein-associated phospholipase A(2) and risk of congestive heart failure in older adults: The Cardiovascular Health Study
-
19808373 10.1161/CIRCHEARTFAILURE.108.839613
-
Suzuki T, Solomon C, Jenny NS, et al. Lipoprotein-associated phospholipase A(2) and risk of congestive heart failure in older adults: the Cardiovascular Health Study. Circ Heart Fail. 2009;2:429-36.
-
(2009)
Circ Heart Fail
, vol.2
, pp. 429-436
-
-
Suzuki, T.1
Solomon, C.2
Jenny, N.S.3
-
83
-
-
62649088880
-
Plasma lipoprotein-associated phospholipase A2 levels in heart failure: Association with mortality in the community
-
18789441 10.1016/j.atherosclerosis.2008.07.035
-
Gerber Y, Dunlay SM, Jaffe AS, et al. Plasma lipoprotein-associated phospholipase A2 levels in heart failure: association with mortality in the community. Atherosclerosis. 2009;203:593-8.
-
(2009)
Atherosclerosis
, vol.203
, pp. 593-598
-
-
Gerber, Y.1
Dunlay, S.M.2
Jaffe, A.S.3
-
84
-
-
80054896732
-
Lipoprotein-associated phospholipase A2 activity in patients with preserved left ventricular ejection fraction
-
21942556 10.3109/1354750X.2011.611597
-
Moldoveanu E, Serban M, Marta DS, Serban I, Huica R. Lipoprotein- associated phospholipase A2 activity in patients with preserved left ventricular ejection fraction. Biomarkers. 2011;16:587-9.
-
(2011)
Biomarkers
, vol.16
, pp. 587-589
-
-
Moldoveanu, E.1
Serban, M.2
Marta, D.S.3
Serban, I.4
Huica, R.5
-
85
-
-
84883821592
-
Interpretation of lipoprotein-associated phospholipase A2 levels is influenced by cardiac disease, comorbidities, extension of atherosclerosis and treatments
-
doi: 10.1016/j.ijcard.2012.09.054
-
Charniot JC, Khani-Bittar R, Albertini JP, et al. Interpretation of lipoprotein-associated phospholipase A2 levels is influenced by cardiac disease, comorbidities, extension of atherosclerosis and treatments. Int J Cardiol 2012. doi: 10.1016/j.ijcard.2012.09.054.
-
(2012)
Int J Cardiol
-
-
Charniot, J.C.1
Khani-Bittar, R.2
Albertini, J.P.3
-
86
-
-
84862177457
-
Inflammatory cytokines in heart failure: Mediators and markers
-
Gullestad L, Ueland T, Vinge LE, et al. Inflammatory cytokines in heart failure: mediators and markers. Cardiology. 2012;122:23-35.
-
(2012)
Cardiology
, vol.122
, pp. 23-35
-
-
Gullestad, L.1
Ueland, T.2
Vinge, L.E.3
-
87
-
-
0023119414
-
Protective effect of verapamil on the cardiac and circulatory alterations induced by platelet-activating factor
-
2435996 10.1097/00005344-198702000-00009
-
Alloatti G, Montrucchio G, Mariano F, et al. Protective effect of verapamil on the cardiac and circulatory alterations induced by platelet-activating factor. J Cardiovasc Pharmacol. 1987;9:181-6.
-
(1987)
J Cardiovasc Pharmacol
, vol.9
, pp. 181-186
-
-
Alloatti, G.1
Montrucchio, G.2
Mariano, F.3
-
88
-
-
0023857309
-
Study of digoxin as inhibitor of the in vivo effects of acetyl glyceryl ether phosphorylcholine (AGEPC) in mice
-
3339951 10.1016/0024-3205(88)90453-5
-
Kelefiotis D, Lanara E, Vakirtzi-Lemonias C, et al. Study of digoxin as inhibitor of the in vivo effects of acetyl glyceryl ether phosphorylcholine (AGEPC) in mice. Life Sci. 1988;42:623-33.
-
(1988)
Life Sci
, vol.42
, pp. 623-633
-
-
Kelefiotis, D.1
Lanara, E.2
Vakirtzi-Lemonias, C.3
-
89
-
-
84876512771
-
Cross-sectional relationship of a Mediterranean type diet to diastolic heart function in chronic heart failure patients
-
10.1007/s00380-011-0190-9
-
Chrysohoou C, Pitsavos C, Metallinos G, et al. Cross-sectional relationship of a Mediterranean type diet to diastolic heart function in chronic heart failure patients. Hear Vessel. 2012;27:576-84.
-
(2012)
Hear Vessel
, vol.27
, pp. 576-584
-
-
Chrysohoou, C.1
Pitsavos, C.2
Metallinos, G.3
-
91
-
-
74149089215
-
Lipid minor constituents in wines. A biochemical approach in the French paradox
-
Fragopoulou E, Demopoulos CA, Antonopoulou S. Lipid minor constituents in wines. A biochemical approach in the French paradox. Int J Wine Res. 2009;1:131-43.
-
(2009)
Int J Wine Res
, vol.1
, pp. 131-143
-
-
Fragopoulou, E.1
Demopoulos, C.A.2
Antonopoulou, S.3
-
92
-
-
33646035790
-
In vivo antiatherogenic properties of olive oil and its constituent lipid classes in hyperlipidemic rabbits
-
16580585 10.1016/j.numecd.2005.07.003
-
Karantonis HC, Antonopoulou S, Perrea DN, et al. In vivo antiatherogenic properties of olive oil and its constituent lipid classes in hyperlipidemic rabbits. Nutr Metab Cardiovasc Dis. 2006;16:174-85.
-
(2006)
Nutr Metab Cardiovasc Dis
, vol.16
, pp. 174-185
-
-
Karantonis, H.C.1
Antonopoulou, S.2
Perrea, D.N.3
-
93
-
-
33750619723
-
Effect of traditional Greek Mediterranean meals on platelet aggregation in normal subjects and in patients with type 2 diabetes mellitus
-
17004898 10.1089/jmf.2006.9.356
-
Antonopoulou S, Fragopoulou E, Karantonis HC, et al. Effect of traditional Greek Mediterranean meals on platelet aggregation in normal subjects and in patients with type 2 diabetes mellitus. J Med Food. 2006;9:356-62.
-
(2006)
J Med Food
, vol.9
, pp. 356-362
-
-
Antonopoulou, S.1
Fragopoulou, E.2
Karantonis, H.C.3
-
94
-
-
1842558537
-
Anti-inflammatory therapy for heart failure
-
15063362 10.1016/j.coph.2003.11.003
-
Matsumori A. Anti-inflammatory therapy for heart failure. Curr Opin Pharmacol. 2004;4:171-6.
-
(2004)
Curr Opin Pharmacol
, vol.4
, pp. 171-176
-
-
Matsumori, A.1
-
95
-
-
33947424811
-
Effect of spironolactone on C-reactive protein levels in patients with heart disease
-
16899309 10.1016/j.ijcard.2006.05.069
-
Godfrey V, Farquharson C, Macdonald JE, Yee CM, Struthers AD. Effect of spironolactone on C-reactive protein levels in patients with heart disease. Int J Cardiol. 2007;117:282-4.
-
(2007)
Int J Cardiol
, vol.117
, pp. 282-284
-
-
Godfrey, V.1
Farquharson, C.2
Macdonald, J.E.3
Yee, C.M.4
Struthers, A.D.5
-
96
-
-
79952810812
-
In vitro and in vivo effects of statins on platelet-activating factor and its metabolism
-
20805097 10.1177/0003319710375089
-
Tsantila N, Tsoupras AB, Fragopoulou E, et al. In vitro and in vivo effects of statins on platelet-activating factor and its metabolism. Angiology. 2011;62:209-18.
-
(2011)
Angiology
, vol.62
, pp. 209-218
-
-
Tsantila, N.1
Tsoupras, A.B.2
Fragopoulou, E.3
-
97
-
-
0026772205
-
Nitrovasodilators inhibit thrombin-induced platelet-activating factor synthesis in human endothelial cells
-
1322663 10.1016/0006-2952(92)90004-3
-
Heller R, Bussolino F, Ghigo D, et al. Nitrovasodilators inhibit thrombin-induced platelet-activating factor synthesis in human endothelial cells. Biochem Pharmacol. 1992;44:223-9.
-
(1992)
Biochem Pharmacol
, vol.44
, pp. 223-229
-
-
Heller, R.1
Bussolino, F.2
Ghigo, D.3
-
98
-
-
0026328150
-
Calcium channel blockade inhibits platelet activating factor production by human umbilical vein endothelial cells
-
1819708 10.1007/BF02536535
-
Tolins JP, Melemed A, Sulciner D, Gustafson KS, Vercellotti GM. Calcium channel blockade inhibits platelet activating factor production by human umbilical vein endothelial cells. Lipids. 1991;26:1218-22.
-
(1991)
Lipids
, vol.26
, pp. 1218-1222
-
-
Tolins, J.P.1
Melemed, A.2
Sulciner, D.3
Gustafson, K.S.4
Vercellotti, G.M.5
-
99
-
-
0026803297
-
Ramiprilat prevents PAF-induced myocellular and endothelial injury in a neutrophil-perfused heart preparation
-
1334351
-
Schror K, Felsch A. Ramiprilat prevents PAF-induced myocellular and endothelial injury in a neutrophil-perfused heart preparation. Agents Actions Suppl. 1992;38(Pt 3):209-16.
-
(1992)
Agents Actions Suppl
, vol.38
, Issue.PART 3
, pp. 209-216
-
-
Schror, K.1
Felsch, A.2
-
100
-
-
0023688530
-
Inhibition of lyso-PAF: Acetyl-CoA acetyltransferase by salicylates and other compounds
-
2903520
-
White HL, Faison LD. Inhibition of lyso-PAF: acetyl-CoA acetyltransferase by salicylates and other compounds. Prostaglandins. 1988;35:939-44.
-
(1988)
Prostaglandins
, vol.35
, pp. 939-944
-
-
White, H.L.1
Faison, L.D.2
|